Making a Positive Impact in the U.S.
At Sanofi, our passion is to prevent, treat and cure illness and disease throughout life. We are driven to improve the health of communities and to find new solutions for patients by combining breakthrough science with advanced technology.
Inspired by the resilience of our patients and strengthened by our heritage, we are always working for new ways to fight chronic, complex and rare diseases with medicines that offer hope for patients and the future of healthcare.
By investing in worthwhile causes, we put our commitment to corporate citizenship into action. We provide contributions to support a diverse range of organizations and initiatives that we believe can make a meaningful difference in the patients we serve and the communities we live in.
We continue to rely on scientific evidence, medical guidance, and government requirements to conduct our business safely and responsibly. To control viral transmission, we will consider:
- Company support for and participation in live 3rd party sponsorship of events, provided the scientific evidence and federal, state, and local rules on controlling community spread of the virus at events and gatherings allows us to do so safely.
- Company support for and participation in medical congresses, provided the scientific evidence and federal, state, and local rules on controlling community spread of the virus at events and gatherings allows us to do so safely.
Sponsorships
A financial contribution to a non-profit organization in connection with specific events (e.g., congresses, annual conferences, conventions, walk-a-thons, etc.). Sanofi may receive benefits, such as booth space, mailing opportunities, etc.
Philanthropic Donations
A financial contribution to a non-profit organization unrelated to Sanofi therapeutic areas to support the mission or independent initiative with a focus on Health Equity, STEM Education Equity and/or Local Community Partnerships.
Healthcare Contributions
A financial contribution to a non-profit organization to support healthcare-related objectives in therapeutic areas where Sanofi operates. Can include support for an organization’s mission or an independent specific initiative by the organization.
Independent Medical Education (IME/CME) grants
A financial contribution to support the independent identification, development, distribution and educational outcomes measurement of accredited and non-accredited independent medical education programs for the purpose of educating Healthcare Professionals.
Fellowships
A financial contribution to support salary for fellows or Post graduates (e.g., physicians/residents, nurse practitioners, physician assistants and genetic counselors).
Rare Genetic Disease Fellowships
APPLICATION PERIOD IS NOW CLOSED
Sanofi is seeking to fund Fellowship positions with the aim of closing independently identified educational gaps among healthcare providers and genetic counselors treating patients with Rare Genetic Diseases, specifically: Fabry Disease, Alport Syndrome, Pompe Disease, Gaucher Disease, GD3, GM2, MPS I, and Acid Sphingomyelinase Deficiency (ASMD) (historically known as Niemann Pick Disease Type A, type A/B, and type B).
These Fellowships are intended to support teaching hospitals, medical schools, or other institutions that provide specialized training and mentoring in Sanofi areas of interest (i.e., the Rare Genetic Diseases specified above), but not directly related to Sanofi therapies or products.
Patient Assistance Foundations
APPLICATION PERIOD IS NOW CLOSED
These contributions provide funding to patient assistance foundations, which independently operate one or more patient assistance programs (funds) that provide financial assistance to qualified patients to help cover their insurance premiums, copayments and/or other medical expenses without regard to their choice of product.
“Applications will be accepted between October 1 and November 15 each year and must cover the fund’s anticipated needs during the following calendar year (Jan. 1 – Dec. 31). Funding for approved applications should be paid by the end of March.”